Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters - Gidal, Barry E.; Maganti, Rama; Laurenza, Antonio; Yang, Haichen; Verbel, David A.; Schuck, Edgar; Ferry, Jim (Epilepsy research, 2017)
Keywords: Adult; Analysis of Variance; Anticonvulsants - blood; Anticonvulsants - pharmacokinetics; Area Under Curve; Clinical pharmacology; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors - pharmacology; Drug Interactions; Drug-drug interactions; Enzyme inhibition; Enzyme Inhibitors - pharmacology; Healthy Volunteers; Humans; Ketoconazole; Ketoconazole - pharmacology; Male; Models, Chemical; Neurology; Perampanel; Pharmacokinetics; Pyridones - blood; Pyridones - pharmacokinetics; Therapeutic Equivalency; Time Factors; Young Adult; FDA; PGTC; tmax; DDI; PBPK; AUC; Cmin; QD; ANOVA; t1/2; BID; AED; BCRP; Cmax; Ketoconazole; CI; ECG; CLint; Perampanel; AUC0-inf; Clinical pharmacology; Enzyme inhibition; Drug-drug interactions; PK; PER; Pharmacokinetics; maximum plasma concentration; US Food and Drug Association; antiepileptic drug; C max; AUC 0-inf; area under the concentration-time curve extrapolated to infinity; t max; primary generalized tonic-clonic; time to C max; electrocardiogram; analysis of variance; twice per day; pharmacokinetics; perampanel; intrinsic retrograde-calculated clearance; physiologically based PK; CL int; half-life; t; C min; area under the concentration–time curve; confidence interval; once per day; drug-drug interaction; trough concentration